

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Atezolizumab in combination with platinum-based
chemotherapy for untreated locally advanced or metastatic
urothelial cancer**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

A comment received during the scope consultation stated that women with bladder cancer have worse outcomes compared to men and that women tend to present with advanced stage, experience differences in quality of life following treatment, and suffer worse cancer-specific mortality.

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

Issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal recommendation. However, the committee can take into account the differences in quality of life and prognosis into its decision.
--

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No.

Approved by Associate Director (name): Jasdeep Hayre

Date: 24 August 2020